Additionally, higher rather than lower circulating levels of the insulin-sensitising and potentially atheroprotective adipokine adiponectin [9] have been shown to be associated with CAN [10] or reduced HRV [11] in patients with type 2 diabetes. Here, ADIPOQ is linked to Crouzon syndrome-acanthosis nigricans syndrome.